Blog
RSS FeedPosted by Michael Wonder on 29 Jan 2021
First COVID-19 vaccine safety update published
29 January 2021 - Today EMA has released its first safety update on a COVID-19 vaccine — Comirnaty. ...
Posted by Michael Wonder on 19 Jan 2021
Global regulators highlight key role of health care professionals in fostering confidence in COVID-19 vaccines
19 January 2021 - EMA has endorsed a joint statement published today by the International Coalition of Medicines Regulatory Authorities ...
Posted by Michael Wonder on 18 Jan 2021
Norway finds no direct link between elderly deaths and vaccine
19 January 2021 - Health authorities in Norway say there's no evidence of a direct link between the recent string ...
Posted by Michael Wonder on 05 Oct 2020
EU regulator starts safety review of coronavirus drug
3 October 2020 - The European Medicines Agency says it has started a safety review after some patients taking the ...
Posted by Michael Wonder on 23 Sep 2020
How incidents with medicines are managed in the EU – a ten year analysis
23 September 2020 - The EU medicines network is supported by a robust regulatory framework with defined processes and clear ...
Posted by Michael Wonder on 15 Sep 2020
European Medicines Agency approves safety label update for Novartis Beovu
14 September 2020 - Novartis worked with the EMA to update the Beovu (brolucizumab) label to guide physicians in their treatment ...
Posted by Michael Wonder on 04 Sep 2020
PRAC recommends revoking marketing authorisation of ulipristal acetate for uterine fibroids
4 September 2020 - A review by EMA’s safety committee has confirmed that 5 mg ulipristal acetate (Esmya and generic ...
Posted by Michael Wonder on 18 Jun 2020
International regulators stress value of safe and effective vaccines
18 June 2020 - EMA has endorsed two statements about the importance, safety and effectiveness of vaccines published today by the ...
Posted by Michael Wonder on 31 May 2020
COVID-19: reminder of the risks of chloroquine and hydroxychloroquine
29 May 2020 - The EMA is reminding health care professionals to closely monitor patients with COVID-19 who are receiving ...
Posted by Michael Wonder on 24 Apr 2020
Reporting suspected side effects of medicines in patients with COVID-19
24 April 2020 - EMA and the national competent authorities are reminding patients with confirmed or suspected coronavirus disease (COVID-19) ...
Posted by Michael Wonder on 23 Apr 2020
COVID-19: reminder of risk of serious side effects with chloroquine and hydroxychloroquine
23 April 2020 - Chloroquine and hydroxychloroquine are known to potentially cause heart rhythm problems, and these could be exacerbated ...
Posted by Michael Wonder on 28 Mar 2020
EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic
27 March 2020 - EMA is aware of recent media reports and publications which question whether some medicines, for instance ...
Posted by Michael Wonder on 11 Dec 2019
Six-year review shows success of the EU signal management system in improving safe use of medicines
11 December 2019 - In the first six years since the implementation of the 2012 EU pharmacovigilance legislation, the EU ...
Posted by Michael Wonder on 07 May 2019
Working together for safe medicines in the EU
6 May 2019 - EMA launches a social media campaign to highlight how the European medicines regulatory network keeps medicines ...
Posted by Michael Wonder on 14 Apr 2019
Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing
12 April 2019 - EMA has started a review of the multiple sclerosis medicine Lemtrada (alemtuzumab) following new reports of ...